Efficacy and Safety of Luspatercept versus Epoetin Alfa in Erythropoiesis-Stimulating Agent-Naïve Patients with Transfusion-Dependent Lower-Risk Myelodysplastic Syndromes: Full Analysis of the COMMANDS Trial
Guillermo Garcia-Manero, MD, presents data from the COMMANDS trial investigating luspatercept in erythropoiesis-stimulating agent-naive patients with transfusion-dependent lower-risk myelodysplastic syndromes.
San Diego United States Guillermo Garcia Manero International Prognostic Scoring System Epoetin Alfa Erythropoiesis Stimulating Agent Na
Source: onclive.com